Drugs / HER2-Peptid-Vakzine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02276300 | Dec 2014 → Jul 2017 | breast cancer, gastric cancer | Technical University of Munich | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2-Peptid-Vakzine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02276300 ↗ |
| Modality | Vaccine | “peptide vaccination targeting HER2/neu” NCT02276300 ↗ |
| Target | ERBB2 | “peptide vaccination targeting HER2/neu” NCT02276300 ↗ |